MIDDLE EAST AND ASIA PACIFIC CELL AND GENE THERAPY MARKET ANALYSIS

Middle East and Asia Pacific Cell and Gene Therapy Market, by Therapy Type (Cell Therapy (Stem Cells, T Cells, Dendritic Cells, and NK Cells) and Gene Therapy (Germline Gene Therapy and Somatic Gene Therapy)), by Indication (Dermatology, Musculoskeletal, Oncology, Immunology, Cardiology & Neurology, and Others), by Technology (Lentiviral Vector, Plasmid DNA, and AAV), and by Region (Middle East and Asia Pacific) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Mar 2022
Code : CMI4981
Pages :425
Formats :
Excel and PDF
Industry : Biotechnology

Middle East And Asia Pacific Cell And Gene Therapy MarketSize and Trends

Middle East and Asia Pacific cell and gene therapy market is estimated to be valued at US$ 2,616.8 million in 2021 and is expected to exhibit a CAGR of 17.3% over the forecast period (2021-2028).

Figure 1. Middle East and Asia Pacific Cell and Gene Therapy Market Share (%), in Terms of Value, By Region, 2021

Middle East and Asia Pacific Cell and Gene Therapy Market – Impact of Coronavirus (COVID-19) Pandemic – Impact on Drug Development and Clinical Trials

While the healthcare industry continues to focus on the development of COVID-19 vaccines and therapies, the COVID-19 crisis had a significant impact on clinical trials in many therapy areas such as oncology, cardiovascular, and others.

Research programs and preclinical operations have been affected across the cell and gene therapies (CGTs) sector, as pharmaceutical businesses have restricted the number of individuals working on-site to keep them safe and comply with regulatory instructions.

The increasing demand for COVID-19-related laboratory consumables such as personal protective equipment and reagents has hampered the research and preclinical development, resulting in supply chain constriction.

Cell and gene therapies (CGTs) are at the forefront of medical advancements in the treatment of serious diseases such as cancer, cardiovascular diseases, and others. Many more CGTs are currently being developed.